CPHI · China Pharma Holdings Inc
United States · RS rating 25 · As of 2026-11-03
| Price | 0.61 USD |
|---|---|
| 1-day change | -0.1% |
| RS rating (overall / 1M / 3M / 12M) | 25 / 42 / 8 / 15 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 24 / 8 / 19 |
| Industry group (rank) | Medical-Generic Drugs (136) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +62.1% |
| Distance from 52-week high | +92.5% |
| Market cap (USD) | $23.9M |